Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multinational clinical study of Methylthioninium-chloride for COVID-19 infections

Next Previous
X
Search
Trial Profile

A multinational clinical study of Methylthioninium-chloride for COVID-19 infections

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Methylthioninium chloride (Primary)
  • Indications COVID 2019 infections
  • Focus Therapeutic Use

    • Most Recent Events

    • 06 Jun 2021 New trial record
    • 13 Apr 2021 According to a Prexa Pharmaceuticals media release, the company expects to initiate this study within the next several months.
    • 13 Apr 2021 According to a Prexa Pharmaceuticals media release, the company had submitted a Pre-IND meeting request to the U.S. FDA, on which a written response-providing the understanding on the requirements for opening an IND for the filing of a New Drug Application (NDA) and eventual Product approval was received. The company has incorporated this guidance into Product-118 program and planning for manufacturing and filing of the NDA, for a multi-national clinical study of Product-118.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top